Table 1.
Baseline characteristics of participants.
| Characteristic | Total population (N = 170) (%) | Population with HLA testing | p-value | ||
|---|---|---|---|---|---|
| HLA-A assessment (N = 91) (%) |
Interested HLA-A subtypes (N = 35) (%) |
Uninterested HLA-A subtypes (N = 51) (%) |
|||
| Age | |||||
| < 60 | 56 (32.9) | 34 (37.4) | 12 (34.2) | 21 (40.4) | 0.648 |
| ≥ 60 | 114 (67.1) | 57 (62.6) | 23 (65.8) | 30 (59.6) | |
| Sex | |||||
| Male | 55 (32.4) | 26 (28.6) | 11 (31.4) | 14 (26.9) | 0.804 |
| Female | 115 (67.6) | 65 (71.4) | 24 (68.3) | 37 (73.1) | |
| Smoking status | |||||
| Never smoker | 138 (81.2) | 80 (87.9) | 31 (88.5) | 46 (88.5) | 1.000 |
| Former/Current smoker | 32 (18.8) | 11 (12.1) | 4 (11.5) | 6 (11.5) | |
| Histology | |||||
| Adenocarcinoma | 142 (83.5) | 81 (89.0) | 31 (88.5) | 46 (88.5) | 1.000 |
| Non-adenocarcinoma | 28 (16.5) | 10 (11.0) | 4 (11.5) | 6 (11.5) | |
| EGFR mutation | |||||
| Exon 19del | 100 (58.8) | 56 (61.5) | 28 (80.0) | 28 (54.9) | 0.056 |
| L858R | 59 (34.7) | 30 (32.9) | 7 (20.0) | 23 (45.1) | |
| Uncommon | 11 (6.5) | 5 (5.6) | |||
| EGFR TKI | |||||
| Gefitinib/Erlotinib | 133 (78.2) | 72 (79.1) | 25 (71.4) | 43 (84.3) | 0.207 |
| Afatinib/Dacomitinib | 9 (5.3) | 4 (4.4) | 2 (5.7) | 1 (1.9) | |
| Osimertinib | 28 (16.5) | 15 (16.5) | 8 (22.9) | 7 (13.8) | |
| Liver metastasis | |||||
| Presence | 31 (18.2) | 14 (15.4) | 6 (17.2) | 8 (15.7) | 0.688 |
| Absence | 139 (81.8) | 77 (84.6) | 29 (82.8) | 43 (84.3) | |
| Intra-tumoral CD8+ (n = 86) | |||||
| CD8 + < 10% | 82 (48.2) | 48 (52.7) | 20 (90.9) | 25 (96.1) | 1.000 |
| CD8 + ≥ 10% | 4 (2.4) | 4 (4.4) | 2 (9.1) | 1 (3.9) | |
| Inadequate tissue | 84 (49.4) | 39 (42.9) | 13 (-) | 25 (-) | |
| Stromal CD8+ (n = 83) | |||||
| CD8 + < 10% | 66 (38.8) | 38 (41.8) | 14 (66.7) | 21 (84.0) | 0.281 |
| CD8 + ≥ 10% | 17 (10.0) | 12 (13.2) | 7 (33.3) | 4 (16.0) | |
| Inadequate tissue | 87 (51.2) | 41 (45.1) | 14 (-) | 26 (-) | |
| PD-L1 TPS 22C3 (n = 93) | |||||
| PD-L1 < 15 | 82 (48.2) | 51 (56.0) | 20 (83.3) | 27 (93.1) | 0.214 |
| PD-L1 ≥ 15 | 11 (6.5) | 7 (7.7) | 4 (16.7) | 2 (6.9) | |
| Inadequate tissue | 77 (42.3) | 33 (36.3) | 11 (-) | 22 (-) | |
| Tumor microenvironment | |||||
| Inflammatory TIME | 14 (8.2) | 10 (11.0) | 5 (22.8) | 3 (11.2) | 0.429 |
| Non-inflammatory TIME | 74 (43.5) | 43 (47.3) | 17 (77.2) | 24 (88.8) | |
| Inadequate specimen | 82 (48.2) | 38 (41.7) | 13 (-) | 24 (-) | |